Raymond James & Associates Brainstorm Cell Therapeutics Inc. Transaction History
Raymond James & Associates
- $146 Billion
- Q1 2024
A detailed history of Raymond James & Associates transactions in Brainstorm Cell Therapeutics Inc. stock. As of the latest transaction made, Raymond James & Associates holds 113,785 shares of BCLI stock, worth $38,686. This represents 0.0% of its overall portfolio holdings.
Number of Shares
113,785
Previous 115,785
1.73%
Holding current value
$38,686
Previous $31,000
103.23%
% of portfolio
0.0%
Previous 0.0%
Shares
19 transactions
Others Institutions Holding BCLI
# of Institutions
52Shares Held
4.09MCall Options Held
63.2KPut Options Held
800-
Vanguard Group Inc Valley Forge, PA1.4MShares$476,3370.0% of portfolio
-
Black Rock Inc. New York, NY489KShares$166,3660.0% of portfolio
-
Geode Capital Management, LLC Boston, MA357KShares$121,3930.0% of portfolio
-
Liberty Wealth Management LLC Oakland, CA340KShares$115,6510.04% of portfolio
-
Weaver Consulting Group199KShares$67,7810.04% of portfolio
About BRAINSTORM CELL THERAPEUTICS INC.
- Ticker BCLI
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 36,486,200
- Market Cap $12.4M
- Description
- Brainstorm Cell Therapeutics Inc., a biotechnology company, engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases. The company, through its NurOwn proprietary cell therapy platform, leverages cell culture methods to induce autologous bone marrow-derived mesenchymal stem ...